GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-3.24%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$484M
AUM Growth
+$484M
(-20%)
Cap. Flow
-$75.9M
Cap. Flow
% of AUM
-15.69%
Top 10 Holdings %
Top 10 Hldgs %
59.62%
Holding
43
New
11
Increased
12
Reduced
4
Closed
14
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$23.1M |
| 2 |
Biogen
BIIB
|
$21M |
| 3 |
Exelixis
EXEL
|
$16.4M |
| 4 |
Travere Therapeutics
TVTX
|
$14.8M |
| 5 |
Lantheus
LNTH
|
$13.9M |
Top Sells
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$45M |
| 2 |
Zymeworks
ZYME
|
$37.8M |
| 3 |
Vericel Corp
VCEL
|
$27.8M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$25.8M |
| 5 |
Theravance Biopharma
TBPH
|
$14.7M |
Sector Composition
| 1 | Healthcare | 94.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MacroGenics
MGNX
$112M
| $43M | 8.89% | 1,350,000 +110,713 | +9% | +$3.53M |
|
2
Rocket Pharmaceuticals
RCKT
$354M
| $33.7M | 6.97% | 760,000 +60,000 | +9% | +$2.66M |
|
3
Iovance Biotherapeutics
IOVA
$807M
| $29.4M | 6.09% | 930,000 +12,573 | +1% | +$398K |
|
|
SAGE
4
DELISTED
Sage Therapeutics
SAGE
| $28.6M | 5.91% | 382,085 -72,332 | -16% | -$5.41M |
|
|
XENT
5
DELISTED
Intersect ENT, Inc
XENT
| $27.8M | 5.75% | 1,332,773 +29,902 | +2% | +$624K |
|
|
6
Exelixis
EXEL
$10.1B
| $27.1M | 5.61% | 1,201,100 +726,100 | +153% | +$16.4M |
|
7
United Therapeutics
UTHR
$13.8B
| $26.2M | 5.41% | 156,406 +6,406 | +4% | +$1.07M |
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $26.1M | 5.39% | 375,870 +30,750 | +9% | +$2.13M |
|
9
Insulet
PODD
$23.9B
| $23.4M | 4.83% | 89,600 +29,600 | +49% | +$7.72M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $23.1M | 4.78% | +135,000 | New | +$23.1M |
|
|
11
Biogen
BIIB
$19.4B
| $21M | 4.34% | +75,000 | New | +$21M |
|
12
Collegium Pharmaceutical
COLL
$1.22B
| $20.4M | 4.22% | 861,410 +440,027 | +104% | +$10.4M |
|
|
CNST
13
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $20.4M | 4.22% | 872,415 -152,385 | -15% | -$3.56M |
|
|
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
| $18.5M | 3.82% | 4,755,000 +671,091 | +16% | +$2.61M |
|
15
Ocular Therapeutix
OCUL
$2.12B
| $16.5M | 3.42% | 1,007,012 +150,850 | +18% | +$2.48M |
|
|
16
Travere Therapeutics
TVTX
$1.56B
| $14.8M | 3.06% | +593,712 | New | +$14.8M |
|
|
17
Lantheus
LNTH
$3.73B
| $13.9M | 2.87% | +649,516 | New | +$13.9M |
|
18
Puma Biotechnology
PBYI
$254M
| $12.6M | 2.61% | 1,300,000 | – | – |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $11.2M | 2.31% | +80,000 | New | +$11.2M |
|
20
InflaRx
IFRX
$108M
| $8.58M | 1.77% | +2,200,000 | New | +$8.58M |
|
21
Acadia Pharmaceuticals
ACAD
$4.38B
| $8.03M | 1.66% | 311,217 -409,285 | -57% | -$10.6M |
|
22
Pulmonx
LUNG
$69.7M
| $5.23M | 1.08% | 114,345 +50,000 | +78% | +$2.29M |
|
|
RDHL
23
Redhill Biopharma
RDHL
$3.1M
| $5.16M | 1.07% | +705,305 | New | +$5.16M |
|
|
RXDX
24
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $4.57M | 0.94% | +250,000 | New | +$4.57M |
|
25
Y-mAbs Therapeutics
YMAB
$388M
| $4.54M | 0.94% | +150,000 | New | +$4.54M |
|